Question

which of the following are true about the CERE – 110 treatment used on Alzheimer's disease patients in the phase 2 clinical trial? It was an AVI vector, it encoded a gene for nerve growth factor, the construct was administered via stereotactic injection, it only tested pre-clinically and rodents, it was given at a dose of one times 10 sixBG per patient, the viral serotype was chosen for its ability to cross the blood brain barrier

Name: which of the following are true about the cere 110 treatment used on alzheimers disease patients in the phase 2 clinical trial it was an avi vector it encoded a gene for nerve growth factor 36824
Uploaded: 2022-09-09T22:41:03-08:00
Duration: 1 min 29 s
Channel: James Kiss
Description: which of the following are true about the cere 110 treatment used on alzheimers disease patients in the phase 2 clinical trial it was an avi vector it encoded a gene for nerve growth factor 36824

          which of the following are true about the CERE – 110 treatment used on Alzheimer's disease patients in the phase 2 clinical trial? It was an AVI vector, it encoded a gene for nerve growth factor, the construct was administered via stereotactic injection, it only tested pre-clinically and rodents, it was given at a dose of one times 10 sixBG per patient, the viral serotype was chosen for its ability to cross the blood brain barrier

Added by Brittany S.

Biology for AP Courses

Julianne Zedalis, John Eggebrecht

Instant Answer

Solved by Expert James Kiss

09/09/2022

Step 1

CERE-110 is a gene therapy that uses an adeno-associated virus (AAV) vector to deliver a gene encoding nerve growth factor (NGF) to the brain. Show more…

Show all steps

Thanks for your feedback!

which of the following are true about the CERE – 110 treatment used on Alzheimer's disease patients in the phase 2 clinical trial? It was an AVI vector, it encoded a gene for nerve growth factor, the construct was administered via stereotactic injection, it only tested pre-clinically and rodents, it was given at a dose of one times 10 sixBG per patient, the viral serotype was chosen for its ability to cross the blood brain barrier